InsideArbitrage Potential Deal Alert: Freeline (FRLN) approached by Syncona Portfolio
October 19, 2023
According to a 13D filing, Syncona Portfolio Limited disclosed a non-binding proposal to acquire Freeline Therapeutics (FRLN) for $5 per ADS in an all-cash deal.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
